ArticleThe Laryngoscope2026
Sentio Bone-Conduction Implant: Early Outcomes in Patients With Conductive or Mixed Hearing Loss.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSentio (Oticon Medical) is an active bone-conduction implant approved in 2024. This study evaluates initial clinical outcomes, safety, and audiological efficacy of the Sentio in patients with conductive or mixed hearing loss.
methodsA total of 28 patients (10 conductive, 18 mixed hearing loss) were implanted with Sentio. Preoperative assessments included pure-tone audiometry and speech recognition testing in unaided and aided conditions. Postoperative evaluations of hearing thresholds and speech recognition were performed in free field. Subjective benefit was assessed using the APHAB questionnaire before and after implantation. The first follow-up occurred 1 month after activation.
resultsAll surgeries were completed without complications. One patient required revision surgery, which was successful. No other adverse events occurred. Mean hearing threshold improved from 56.3 dB HL (unaided) and 31.7 dB HL with Ponto on a softband to 25.3 dB HL post-activation and remained stable at 1-month follow-up (p < 0.001). Speech discrimination was 11.9% preoperatively (unaided) and 85.5% with Ponto. It reached 87.3% at activation and 93.3% at the follow-up (p < 0.001). Speech perception in noise was +1.97 dB SNR before implantation (unaided) and 2.22 dB SNR (aided), -2.04 dB SNR at implant activation and -2.67 dB SNR at the follow-up (p < 0.001 for implant conditions vs. unaided). APHAB global score decreased from 53.2 points preoperatively to 32.6 points postoperatively (p < 0.001).
conclusionSentio implantation appears effective and safe for the rehabilitation of conductive or mixed hearing loss. The first clinical results demonstrate audiological improvement and subjective benefit, supporting the potential of the system as a reliable bone-conduction hearing solution. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.